207_Combined course Presentations

Toxicity of concurrent SRT and ALK-inhibitors

crizotinib, ceritinib, alectinib

available data does not allow for a robust

conclusion on safety of combined crizotinib,

ceritinib, alectinib and SRT.

Kroeze S et al. Cancer Treatment Reviews 53 (2017) 25–37